Adaptimmune Therapeutics (ADAP) Life Sciences Investor Forum 2024 summary

Company history and platform

• Founded 16 years ago to revolutionize cancer treatment with cell therapy, focusing on solid tumors where CAR-T therapies are less effective.

• Developed a T-cell receptor (TCR) engineering platform to target a wide range of solid tumors.

• Built integrated capabilities from protein engineering to clinical manufacturing for autologous cell therapies.

• Pipeline includes multiple engineered TCR therapies, with Tecelra as the lead product.

Tecelra approval and clinical impact

• Tecelra approved by FDA in August for synovial sarcoma, marking the first engineered cell therapy for a solid tumor.

• Demonstrated a 43% response rate in single-arm trials, significantly higher than previous therapies.

• Responses are durable, with 40% lasting over 12 months and a 2-year survival probability of 70% for responders.

• Offers a one-time treatment, contrasting with ongoing, often debilitating therapies.

Patient population and market opportunity

• Synovial sarcoma primarily affects young adults, with most diagnosed at a metastatic stage and a 20% five-year survival rate.

• Estimated 1,300 cases annually in the US, with about 400 eligible for Tecelra based on biomarkers.

• Rare disease commercialization model targeting high agency, motivated patients.

• Combined US market opportunity for Tecelra and lete-cel estimated at $400 million.